Published in final edited form as:

J Perinat Neonatal Nurs. 2019 ; 33(1): 35–51. doi:10.1097/JPN.0000000000000375.

Through the Microbial Looking Glass: Premature Labor, Preeclampsia, and Gestational Diabetes: A Scoping Review

Alexis B. Dunn, PhD, CNM [Assistant Professor],

Nell Hodgson Woodruff School of Nursing at Emory University, Atlanta GA

Lisa Hanson, PhD, CNM, FACNM [Professor and Director],

Nurse-Midwifery Program at the Marquette University College of Nursing, Milwaukee Wisconsin

Leona VandeVusse, PhD, RN, CNM, FACNM [Associate Professor Emerita], and

Marquette University College of Nursing, Milwaukee Wisconsin

Sharon Leslie, MSLS, AHIP [nursing informationist]

Woodruff Health Sciences Center Library at Emory University, Atlanta GA

INTRODUCTION

Pregnancy is characterized by a variety of microbiological, immunologic, and inflammatory changes that promote the health of both the mother and developing fetus.^{1,2} The microbiome composition of the maternal gut changes dramatically between the first and third trimesters of pregnancy. These changes include increased β -diversity (differences between pregnant women), an overall increase in Proteobacteria and Actinobacteria, and reduced richness (lower number of species).³ Similarly, the vaginal microbiome composition changes substantially during the course of normal pregnancy. Diversity decreases, stability increases, and the vagina is enriched with *Lactobacillus* species.⁴ Vaginal pH becomes more acidic, while vaginal secretions are increased. However, by the third trimester, the vaginal microbiota resembles that of the nonpregnant state.⁴

Host microbial interactions between the mother and infant during pregnancy and the timing of the first exposure of the fetus to maternal microbes are not fully understood, although the largest exposure is thought to occur at birth.⁵ Historically the intrauterine environment was thought to be germ free, however newer evidence suggests that a bacterial milieu may be present in the fetoplacental circuit.^{4,6,7} Microbial exposures and alterations have been implicated in the etiology of several adverse perinatal outcomes, including preeclampsia (PEC), preterm birth (PTB), and gestational diabetes (GDM).^{8,9} Recent investigations exploring the contributions of the human microbiome (defined as the total collection of microbes and their genetic characteristics)¹⁰ have become the focus of recent scientific inquiry in understanding the etiologic mechanisms of these obstetrical syndromes.^{11–13}

Corresponding Author: Alexis B. Dunn, PhD, CNM, 1520 Clifton Road, NE, Atlanta, GA 30322, Ph: 770-298-2358 /Fax: 404-727-6945, alexis.b.dunn@emory.edu.

The authors have no conflicts of interest to disclose.

BACKGROUND

Completed in 2012, the Human Microbiome Project characterized microbial communities and their respective physiologic activities in a variety of body sites, including the nasal passages, oral cavity, urogenital system, and gastrointestinal tract.¹⁴ The initiative generated health reference data for a variety of microbiome sites, including those associated with normal pregnancy.^{3,4} Utilizing advanced molecular genetics and genomics technology, a variety of DNA sequencing technologies including 16S (gene) based analysis, as well as whole genome shotgun sequencing (entire bacterial DNA sequence of an organism) have allowed for both characterization of the types of microbes present in select body sites, as well as their genetic coding patterns and metabolic capacity.^{15,16} Advances in genomic analyses and the development of bioinformatics communication channels, such as Quantitative Insights into Microbial Ecology (QIIME) and Mothur (a microbiome software platform), have streamlined the process of sharing the taxonomic information identified in these analyses.^{17,18} Further, these bioinformatic resources provide detailed information about the composition of body sites and the influence on host physiology, which are key in understanding health outcomes.

The closely related area of microbial interventions has received considerable attention worldwide. Probiotic interventions contain live, usually freeze-dried bacterial microbes, often from the *Lactobacillus* and/or *Bifidobacterium* genera.¹⁹ When given in sufficient quantities, probiotic bacteria confer health benefits on the host.²⁰ Probiotics are considered food. For use in antenatal applications, probiotic interventions can be administered either orally or vaginally. In most studies involving pregnant women, the oral route was used.¹⁹ Prebiotic interventions administered orally are not live bacteria, but rather comprised of indigestible food substances, such as dietary fibers, certain starches, and oligosaccharides that are selectively fermentable.²¹ Prebiotics are food for the probiotic bacteria and therefore increase microbial numbers. Synbiotics are a combination of probiotic and prebiotic interventions.²² Synbiotics produce beneficial effects by promoting the survival of the live microbes in the gut by stimulating growth and/or metabolic activity of one or more probiotic bacteria. Probiotic interventions, and to a lesser extent, prebiotics, have been applied during pregnancy to improve maternal and fetal outcomes.¹⁹ More recently, synbiotic antenatal interventions have been studied.^{23,24}

The purpose of this scoping review is to explore and synthesize the scientific evidence about the maternal and neonatal consequences of microbial dysbiosis, with a focus on the role of the microbiome during pregnancy, as well as the influence of prebiotic and probiotic exposures. Specifically, this review outlines the most recent literature on perinatal microbiome and probiotics, prebiotics, and synbiotics specific to the maternal and neonatal outcomes in pregnancies that are complicated by PEC, PTB, or GDM. A brief review of the implications for the neonate as well as future clinical and research implications are discussed.

METHODS

A comprehensive literature search of four databases (PubMed, [Embase.com](https://www.embase.com/), Web of Science Core Collection and the Cochrane Database of Systematic Reviews) was undertaken to identify relevant articles. A scoping review strategy was chosen as the review method, as research studies investigating the impact of microbiome and probiotics on adverse perinatal outcomes have not been comprehensively explored.²⁵ To assure that the full breadth and depth of the literature was explored, the searches were developed and conducted by an experienced medical librarian with input from the research team. This review was conducted using the standards established by the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines, which advocate for systematic and reproducible methods. Search strategy details are provided in Table 1. The results were exported to EndNote and reviewed by the clinical authors.

Articles were included if published in English between January 1, 2008, and August 10, 2018, to capture the most recent evidence in line with the Human Microbiome Project that launched in 2008. The searches combined controlled vocabulary supplemented with keywords related to the concepts of the microbiome (e.g., microbiota, prebiotics, probiotics, synbiotics); PEC (e.g. pre-eclampsia, eclampsia); GDM (e.g., pregnancy, diabetes mellitus); and PTB (e.g., pre-term birth, premature birth). Grey literature (e.g. scholarly, but not commercially published documents such as conference abstracts or proceedings, government reports, white papers and theses) were not included.

Following the database searches, articles were selected if they met the inclusion criteria: (a) reported findings about PEC, GDM, or PTB AND; (b) reported outcomes of prebiotic and probiotic interventions; or (c) evaluated the composition of the maternal microbiome. Article quality was not assessed, but rather the types of studies were categorized to offer the most comprehensive review of the state of the science on the topics. The articles included in this scoping review were limited to: level 1 experimental designs (randomized controlled trials (RCTs) or systematic reviews of RCTs); level 2 quasi-experimental designs; level 3 observational analytic designs (systematic review of cohort study, cohort study with control group, case-controlled study); and level 4 (observational descriptive and cross-sectional studies).²⁶ Titles and abstracts were initially reviewed to determine first round inclusion; full text were later reviewed for final decisions about inclusions. Articles were excluded if not directly related to the select perinatal outcomes (PEC, GDM, PTB), or if the study did not clearly measure the microbiome, prebiotic, probiotic, or symbiotic-related concepts. The PRISMA flow diagram is presented in Figure 1. A series of tables are used to present the literature. Table 2 contains the systematic reviews and meta-analyses.^{27–35} Table 3 presents the findings of individual trials: randomized controlled trials (RCTs), prospective cohort studies, retrospective cohort studies, and a case control study.^{23,24,36–49} Studies of the microbiome and the perinatal outcomes of PEC, GDM, and PTB are presented in Table 4.^{12,50–66}

A total of 1,264 articles were identified through the database searches. Duplicates (396) were excluded leaving 868 articles to be screened in the initial abstract screening phase. Forty-nine were eligible for full-text review. Five articles were excluded during the full-text

review phase, leaving 44 articles that met all the eligibility criteria for inclusion in this study. In the following sections, the most recent evidence related to Preeclampsia, Gestational Diabetes Mellitus, and Preterm Birth will be presented. Details of the types and dosages of prebiotic, probiotic and synbiotic interventions are beyond the scope of this review but can be found in the individual studies.

RESULTS

The Role of the Microbiome in Preeclampsia

Preeclampsia (PEC) is a multi-system pregnancy complication characterized by new onset hypertension with proteinuria, or evidence of systemic disease primarily in the liver and kidneys, with onset after 20 weeks gestation.⁶⁷ The etiologic pathways of PEC are multifactorial and include maternal and fetal factors; however, the full pathway is not fully elucidated. The disorder is characterized by impaired vascular function and activation of maternal systemic inflammation in several organs, which can be aggravated by many factors, including infection. Studies have shown that women with asymptomatic bacteriuria, urinary tract infection, periodontal disease, and chronic pyelonephritis are at increased risk for PEC.^{50,68} As such, the current focus of scientific inquiry has shifted to learning more about the role of the microbiome in the multifactorial pathway of PEC.

One of the focal areas in recent microbiome studies of PEC is vascular dysfunction in the placenta, which has been implicated as one of the leading pathways underpinning the disorder.⁶⁷ In a nested case-control study, researchers compared the placental tissue of women with PEC to normotensive women to screen the samples for the presence of bacteria. Using polymerase chain reaction (PCR) and next generation sequencing methods, the researchers found that 12.7% of the placenta samples of women with PEC were PCR positive for the 16S rRNA gene. The microbiome of the samples identified a variety of commensal and pathogenic bacteria, including *Listeria*, *Salmonella*, and *Escherichia*.¹² Similarly, Nizyaeva et al. explored the differences in the histological and microbial features of PEC in a nested case-control study. The sample included 20 reproductive age women with the disorder and 12 normal controls, all of whom were between 26 and 39 weeks gestation.⁵² Forty-five percent of the women with PEC demonstrated chronic villitis ($P<0.05$) as compared to the control group at 8%. All placentas were cultured; 25% of the PEC group demonstrated pathologic microbial growth (including *Streptococcus agalactiae* or Group B *Streptococcus* and *Staphylococcus warneire*), while all the control group placentas were culture negative. Placental microbes were only identified in women with PEC who delivered after 34 weeks of gestation, suggesting that microbial pathways may be particularly important to consider in women during later pregnancy. Together, these study findings suggest that microorganisms may contribute to an inflammatory response and support the role of microbial interactions in the etiologic pathway of PEC.

Infection and inflammation have also been implicated in the complex pathway of PEC,^{68,69} with some focus on the influence of microbes within the intrauterine cavity. In a retrospective cohort investigation, DiGiulio et al⁵⁰ found that women with PEC who had microbial invasion of the amniotic cavity demonstrated a higher mean amniotic fluid IL-6 level ($P=.002$). The prevalence of microbial invasion overall in women with PEC was found

to be low, although three of the six women with microbial invasion were positive for *Sneathia/Leptotrichia* spp,⁵⁰ which are microbiota associated with bacterial vaginosis (BV) and isolated cases of maternal bacteremia and fetal demise.^{70,71} Although microbial invasion of the intra-amniotic environment has been identified in women with PEC, more studies are needed to elucidate the pathways by which microbes influence the intrauterine physiology.

The association between maternal periodontal disease and preeclampsia risk was explored in two studies, a meta-analysis⁶⁹ and a secondary analysis of a RCT.⁵¹ In a recent meta-analysis of 11 observational studies including 1,118 women with PEC compared to 2,798 women, researchers found that women with periodontal disease before 32 weeks gestation had a 3.6-fold increased risk of PEC (OR=3.69; 95% CI 2.58–5.27) compared to women without gum disease.⁶⁹ The risk was also increased if periodontal disease was present 48 hours prior to delivery (OR=2.68, 95% CI 1.39–5.18), as well as within five days after delivery (OR=2.22; 95% CI=1.16–4.27). In a secondary analysis of a RCT conducted by Jaramillo et al,⁵¹ the subgingival microbiota of 57 women with mild PEC were evaluated for differences related to a periodontal intervention (subgingival scaling and planing versus supragingival prophylaxis). There were no differences found in reduction of periodontopathic organisms between the two groups.⁵¹ Despite these findings, the relationship between the oral microbiome and PEC risk remains hypothetical, as most of the current literature consists of proposed pathways related to hematogenous spread of microbial pathogens from the oral environment.^{1,72–75} A variety of oral microbial pathogens have been implicated in the etiology of PEC in previous studies, but not enough evidence has been identified to support a causal link.⁷⁶ More research is needed to determine whether there is an association between the oral microbiome and PEC risk.

Preeclampsia has features similar to metabolic syndrome, as women with this condition often develop altered glucose and lipid metabolism, insulin resistance, and endothelial damage.⁷⁷ Given the role of the gut microbiota in metabolism, a recent study by Liu et al evaluated the gut microbiome of women with PEC to determine if intestinal dysbiosis could be detected as a marker.⁵³ One hundred women were grouped into four categories: 26 women with PEC and three healthy control groups in the first, second, and third trimesters of pregnancy. The dominant bacterium present in all samples was Bacteroidetes, however, in PEC women there was an overall increase in pathogenic bacteria. Specifically, *Clostridium perfringens* ($P=0.03$) and *Bulleidia moorei* ($P=.00$) increased in women with PEC, with a decrease noted in the probiotic bacteria *Coprococcus catus* ($P=.03$). These findings suggest that there may be a shift in the gut microbial composition in women with PEC.

Overall, five groups of investigators studied the microbiome of PEC.^{12,50–53} In two studies, the placenta site was analyzed;^{12,52} in the remaining three, the mouth,⁵¹ gut,⁵³ or an intra-amniotic⁵⁰ site were examined. Some findings supported the association between pathogenic bacteria and PEC, but this was not a consistent finding. Further, specific pathogenic organisms were not identified in common between the studies on PEC.

Probiotic Use and Preeclampsia

The pathophysiologic pathways underpinning preeclampsia are complex and not fully elucidated, however, maternal immune system dysregulation and infections were associated

with PEC risk and severity.⁷⁸ Probiotics are thought to reduce both systemic and placental inflammation, thus reducing PEC risk.³⁶ Probiotics such as *Lactobacillus acidophilus* and *Lactobacillus rhamnosus* were shown to influence gene regulatory pathways and expression in immune response pathways of the human gut mucosal lining,⁷⁹ further supporting the exploration of probiotics as an intervention to delay and reduce the incidence of PEC.

Several studies investigating the association between probiotic products and PEC suggest a beneficial effect of probiotics in reducing PEC risk.^{27, 36, 38} A large prospective Norwegian Mother and Child Cohort Study (NMCCS) was conducted from 1999–2009 and included data from 108,000 pregnancies. Using these data, Brantsaeter et al³⁶ conducted a prospective cohort study of the relationship between probiotic ingestion in early pregnancy and the risk of PEC in a sample of 33,399 primigravidas.³⁶ In Norway, there are two main probiotic milk products that are consumed. The probiotic beverages deliver 10⁸ probiotic bacteria/ml. Therefore, the authors calculated the probiotic dose based on dietary recall of these standard products. The researchers categorized dietary probiotic ingestion as follows: none, low, moderate, and high. Just over 5% (1,755 women) developed PEC. High level probiotic intake (median 200 ml/day with daily ingestion) was associated with a significant reduction in all PEC (OR=0.80, 95% CI: 0.66–0.96) and severe PEC (OR=0.61, 95% CI: 0.43–0.89). These findings were also reported in a systematic review by Lindsay et al,²⁷ who explored the use of probiotics during pregnancy with maternal outcomes, including PEC. Seven articles were identified in the review, although only one study was identified related to PEC risk. Nordqvist et al³⁸ conducted a secondary analysis of the NMCCS to explore probiotic intervention timing. Specifically, they analyzed probiotic milk intake before pregnancy, during early pregnancy, and during late pregnancy, with PEC risk in nulliparous women (n=37,050). The researchers found that probiotic milk intake in late pregnancy, but not before or during early pregnancy, was associated with lower PEC risk (OR=0.80, 95% CI:0.68–0.94).³⁸ Together these studies suggest that probiotic intake was associated with reduced PEC risk.

While the etiology of PEC remains unclear, the markers of hypoxia, oxidative stress, and hemolytic pathways, including hemolysis, elevated liver enzymes, and low platelets have been observed in women with PEC.⁸⁰ Therefore, the physiologic consequences of PEC extend beyond the maternal environment and contribute to fetal complications. A study by Ekambaram et al³⁷ investigated the antihemolytic and antioxidant efficiency of two probiotic yeasts (*Monascus purpureus* and *Saccharomyces cerevisiae*) on fetal cord blood red blood cells (RBC) of infants born to PEC mothers as compared to healthy normotensive controls. The red blood cells of the PEC sample were found to have low anti-oxidant status ($P<0.05$), increased oxidative stress, ($P<0.05$), increased nitrative stress ($P<0.05$), and increased hemolysis ($P<0.001$). Oxidative stress hemolysis decreased in the cord blood RBC for both groups after incubation with both probiotic yeasts. Specifically, *M. purpureus* resulted in significant reactive oxygen radical scavenging (removal) ($P<0.001$), and *S. cerevisiae* resulted in significant nitric oxide radical scavenging (removal) ($P<0.001$). These findings hold promise that probiotics could modulate oxidative stress in offspring.

The Role of the Microbiome in Gestational Diabetes Mellitus

The normal physiologic adaptations of pregnancy provide for the metabolic needs of the growing fetus. Gestational Diabetes Mellitus (GDM) is defined as a carbohydrate intolerance with hyperglycemia with onset during pregnancy that varies in severity.⁸¹ Gestational Diabetes Mellitus is a heterogeneous group of metabolic disorders that impacts up to 14% of pregnancies.⁸² Between 20–50% of women with GDM will go on to be diagnosed with Type 2 diabetes within five years.⁸³ Evidence has emerged that highlights the link between the gut microbiome and metabolism. This has led researchers to hypothesize that the gut microbiome may impact gestational metabolism and development of GDM.⁵⁵ The microorganisms that colonize the gut influence the metabolism of nutrients, hunger, satiety, and both lipid and glucose metabolism. Gestational Diabetes Mellitus has been associated with subclinical inflammation that may lead to oxidative stress.⁴⁰ Therefore, efforts to prevent and treat GDM have included probiotic and/or dietary interventions. Outcomes studied include a variety of metabolic and inflammatory markers.

Four groups of researchers examined the microbiome related to GDM.^{54–57} The sites cultured varied widely between studies; stool was cultured in two studies,^{54–55} vaginal swabs to examine fungi were used in one study,⁵⁷ and in another study, both viruses and bacteria were examined from three sites in women (oral, gastrointestinal, and vagina) and four sites from their newborns (oral, pharynx, meconium and amniotic fluid).⁵⁶ Dysbiosis was identified more frequently in women with GDM, who also exhibited less overall microbial diversity.⁵⁵ More pathogens were found in women with GDM, including more viruses and fungal species.⁵⁶ The relationships between dysbiosis and GDM needs to be more fully elucidated.

Probiotic Use and Gestational Diabetes Mellitus

GDM probiotic and synbiotic interventions have been addressed in nine RCTs and seven systematic reviews and/or meta-analyses. In seven of the RCTs, participants were randomized after GDM diagnosis to probiotic or placebo groups.^{23,24,39,41–44} The effect of a probiotic intervention on inflammatory markers and oxidative stress in GDM was the goal of one study.⁴⁰ Other outcomes attributable to the probiotic intervention are somewhat variable between RCTs. Both C-reactive protein and tumor necrosis factor were significantly decreased among probiotic group participants compared to placebo in two studies.^{40,41} Women in the probiotic intervention groups had lower rates of GDM, compared to those taking placebos in two studies.^{45,46} Fasting blood sugar was significantly decreased in probiotic group participants in three RCTs.^{39,42,43} A review of the meta-analyses/systematic reviews allowed more patterns to emerge. Two systematic reviews/meta-analyses have near identical findings.^{30,32} Probiotic interventions resulted in a significant decrease in fasting serum insulin, and HOMA model assessment for insulin resistance.^{28,30,32} Overall in the meta-analyses, outcomes related to lipids, gestational age, and inflammatory markers did not reach statistical significance.

The Role of the Microbiome in Preterm Birth

During pregnancy, the vagina is dominated by *Lactobacillus* species and characterized by less richness and diversity, but more stability, compared to the nonpregnant vaginal

microbiome.⁸⁴ The bacteria of the vaginal microbiome have been classified into five Community State Types (CSTs).^{59,85} CST-I to CST-III and CST-V are characterized by high levels of high levels of specific species of *Lactobacillus*. Vaginal *Lactobacilli* species include: *Lactobacillus acidophilus*, *fermentum*, *crispatus*, and *jensenii*.⁸⁶ These *Lactobacilli* contribute to a protective biofilm on the vaginal mucosa.⁸⁷ Some *Lactobacillus* species produce lactic acid that acidifies the vaginal mucosal and prevents the adherence of pathogens.⁸⁸ Probiotic bacteria also secrete other substances that are associated with vaginal health (bacteriocins, vitamins, and cytokines).⁸⁸

At least 30% of premature labors are associated with maternal infection.^{35,84,89,90} Microbial pathogens can reach the uterine cavity through three routes that can lead to infection: (a) ascending from the vagina and cervix, (b) retrograde seeding from the abdominal cavity through the fallopian tubes, and (c) hematogenous seeding through the placenta.⁸⁹ At the level of the maternal mucosal surface, some microorganisms secrete phospholipase A2 that acts on phospholipids to form arachidonic acid, which ultimately converts to prostaglandins (PG, PGE2, PGF2A). Other microorganisms secrete endotoxins that stimulate a cascade of proinflammatory cytokines.⁹⁰ These microbial pathways work together to magnify the inflammatory response and contribute to the degradation of the collagen matrices of the cervix, fetal membranes, placenta and uterus.⁹⁰

Among the studies reviewed, a number were designed to examine the microbial aspects of these inflammatory pathways to predict Preterm Birth (PTB). Preterm Birth is associated with higher α -diversity (intra-individual) of vaginal flora.⁶³ CST-IV^{59,85} is associated with Bacterial Vaginosis (BV) and is characterized by mixed community types, enriched in various anaerobic bacteria, with low levels of *Lactobacillus*. Bacterial Vaginosis is a microbial dysbiosis associated with a 40% increase in the risk of PTB.³⁵ When BV occurs there is a shift from a predominance of *Lactobacilli* populations to a higher proportion of other organisms: *Gardnerella vaginalis*, *Prevotella bivia*, *Mobiluncus sp.*, *Mycoplasma hominis*, and *Atopobium vaginae*.⁸⁵ This results in the characteristic vaginal secretions with a number of common clinical findings, including: pH ≥ 5.5 , presence of clue cells, and positive whiff test.⁹¹ Therefore, probiotic interventions have been used to address the BV dysbiosis in an effort to reduce the risk of PTB.

Nine groups of researchers examined the microbiome related to PTB.^{58–66} Three of the studies that examined PTB do not lend themselves to comparison because each investigative group sampled a different body site.^{58,61,62} In the six studies^{59,60,63–66} that used vaginal microbial samples, all focused on BV-related assessments, including CST-IV categorization, the presence of BV-associated bacteria, and/or a decrease in *Lactobacillus* dominance. One study reported viruses present.⁶⁶ In the systematic review by Mendz et al³⁴ (Table 2), the bacterial etiology of intra-amniotic infections was examined. Vaginal organisms were responsible for most intra-amniotic infections.³⁴

In three investigations, race was explored as a possible factor in PTB, in relationship to the microbiome.^{63,64,66} Hyman et al⁶³ reported that significant correlations were identified between race/ethnicity and diversity in the vaginal microbiome. Using the Shannon Diversity Index as the measure, African American women had the greatest diversity of

microbes, Caucasians had the least ($P = .003$). Hispanics had the second most diverse vaginal microbiome ($P = .0082$) compared to Caucasians. Caucasian women who experienced PTB had greater microbial diversity compared to those who had term births ($P = .00016$).⁶³ Wylie et al⁶⁶ reported higher richness and diversity in the virome of women who experienced PTBs in the total sample ($P = .0005$) and those in the African American subgroup who had PTBs ($P = .0003$). For the entire sample, both high diversity of bacteria and viruses in the first trimester were associated with the highest risk for spontaneous PTB ($P = .01$), while lower combined diversity was associated with term birth ($P < .0001$). Subramaniam et al⁶⁴ examined their small sample which was stratified by race and determined that the microbiota did not differ by racial groups.

Probiotic Use and Preterm Birth

Due to the variation in premature labor diagnosis in most studies reviewed, PTB (<37 weeks and/or <34 weeks) were used as the primary study outcomes. Two systematic reviews and four clinical studies explored the efficacy of probiotic interventions to reduce PTB risk. Othman et al³⁵ conducted a systematic review of probiotic interventions to prevent premature labor. Three studies met their inclusion criteria; the impact of probiotic interventions on vaginal infection was based on two trials including a total of 99 participants. The researchers found that probiotic use reduced the risk of genital infection by 81% (RR 0.19; 95% CI 0.08 to 0.48). However, they found insufficient evidence for utility of probiotic intervention for the prevention of premature labor.

Using participants in the NMCCS prospective cohort study, Myhre et al⁴⁹ explored the relationship between the ingestion of probiotic containing yogurt products and premature labor, using a sample of 18,888 Norwegian women. Probiotic intake was calculated using dietary histories and operationally defined as low, average, or high. The average probiotic intake in the high group was 138.4 ml/day per day. Between 2002–2007, there were 950 cases of PTB <37 weeks. Women with the “highest” intake of probiotic yogurt experienced significantly lower risk of PTB ($P = .035$; OR: 0.820; 95% CI: 0.681, 0.986).

Jarde et al³³ conducted a systematic review of pregnancy outcomes in women taking probiotics or prebiotics. In two meta-analyses, the authors found no evidence that probiotic interventions altered the incidence of PTB <34 weeks (RR 1.03, 95%, CI 0.29–3.64, I^2 0%, 1,017 women in 5 studies) or PTB <37 weeks (RR 1.08, 95%, CI 0.71–1.63, I^2 0%, 2,484 women in 11 studies). A significant limitation of these meta-analyses is the inclusion of studies of women from high-risk groups, such as obese women²⁷ and those with GDM.^{27,41} The heterogeneity of the studies included in these meta-analyses make interpretation of the findings difficult. For example, only one of the 11 studies in the meta-analyses aimed to reduce PTB using a probiotic intervention.⁴⁸

Krauss-Silva et al⁴⁸ enrolled healthy pregnant women in a RCT using two *Lactobacillus* species (*L. rhamnosus* GR-1 and *L. reuteri* RC-14) aimed at treating asymptomatic BV infections and ultimately PTB <34 weeks gestation. At the time of publication of preliminary findings, the study sample was insufficient to draw conclusions about intervention efficacy. More recently, Kirihiara et al⁴⁷ studied women at high risk for PTB in a RCT. Bacterial Vaginosis was prophylactically treated with a probiotic combination product

(*Streptococcus faecalis*, *Colstridium butyricum*, and *Bacillus mesentericus*) versus a placebo from 12.5 $\pm$ 5 weeks until the time of birth. Findings demonstrated that women in the probiotics group had significantly less spontaneous PTB, increased gestational age, decreased intrauterine infections, and higher rates of normal vaginal flora.

DISCUSSION

There was significant variation in the findings from studies investigating role of the microbiome during pregnancy, as well as the influence of prebiotic, probiotic, and synbiotic exposures in women with PEC, GDM, and PTB. Some findings supported the association between pathogenic bacteria and these perinatal outcomes, but this was not a consistent finding. Further, specific pathogenic organisms were not identified in common between studies. Probiotic exposures appear to have a beneficial effect in decreasing PEC and GDM risk and also appear to decrease the risk for PTB via the reduction of vaginal infections such as bacterial vaginosis.

Preeclampsia

The relationships between the microbiome, prebiotic, probiotic, or synbiotic use, and the risk for PEC are not fully understood. However, the findings of this review suggest that more research is justified given the findings that: (a) placental tissues of women with PEC were found to harbor pathogenic microbes along with signs of placental inflammation and (b) probiotic use is associated with a reduction in PEC risk. Although there were a limited number of studies identified, the findings suggest that more research is needed to explore these biological mechanisms as viable pathways in the complex pathophysiologic pathway underpinning PEC. Future well-controlled RCTs to explore causal relationships between probiotic use and PEC risk are needed

It may be beneficial to explore the relationships between the microbiome, microbial interventions, and PEC incidence in high-risk groups. Considering the inflammatory state of obesity and the increased risk of hypertensive disorders of pregnancy among obese pregnant women, a recent study associated with a RCT (Study of Probiotics in Gestational Diabetes) explored whether select gut microbes and metabolites among obese pregnant women influenced gestational blood pressure. Overweight and obese pregnant women were found to have gut-associated metabolites (odoribacter and butyrate) that inversely correlated with systolic blood pressure endothelial markers (plasminogen activator inhibitor 1), suggesting that the microbiome may influence blood pressure regulation in pregnancy.⁹² Future microbiome related studies among obese pregnant women may prove beneficial in understanding the pathology of PEC and GDM, given the increased prevalence of obesity.

Preterm Birth

The volume of microbiome studies seeking to identify bacterial communities associated with PTB is extensive. Researchers, utilizing descriptive and correlational studies, attempted to find microbial predictors of premature labor. While all the RCTs sought to reduce PTB risk, ^{38,47,49} prevention and treatment of infections using probiotic interventions, particularly for

BV, were important aims.^{35,48} Probiotics have been shown to be an effective independent or adjunctive therapy for BV.⁹³

Disparities in perinatal outcomes disproportionately impact African American women and their families. The findings of this scoping review suggest that the vaginal flora of African American women may predispose them to PTB risk. Customized nutritional interventions with prebiotics, probiotics, or synbiotics⁹⁴ may offer low-risk strategies for primary prevention.

Premature labor and birth are often the result of polymicrobial infection⁹⁵ with organisms of vaginal origin.³⁴ Vaginal dysbiosis increases the risk of preterm premature rupture of the membranes and neonatal sepsis.⁶⁰ Based on the studies reviewed, these findings provide opportunities for effective prevention and/or intervention at the microbial level. Studies on microbial aspects of PTB prevention require adequate statistical power to demonstrate efficacy of interventions.

Gestational Diabetes

Since GDM is nonacute and diagnosed at predictable intervals during pregnancy, it is compatible with prospective study. Thus, GDM has received considerable attention in RCTs of probiotic interventions. Healthy women were enrolled in two studies.^{45,46} Findings from both studies demonstrated that probiotic interventions reduced the incidence of GDM.^{45,46} The remaining RCTs used samples of women with GDM and focused on interventions with probiotics to improve metabolic outcomes. In contrast, there is a dearth of research on the microbiome associated with GDM. Since inflammation is associated with GDM, more research in this area is warranted.

Although not detailed in this review, *Bifidobacterium* and *Lactobacillus* were the most studied species of probiotics in GDM randomized controlled trials. Probiotic strains and dosages varied greatly between studies. For example, one study used only one million colony forming units (CFUs) of a single probiotic strain,⁴³ while another used a multi-species probiotic with one trillion CFUs.⁴¹ In their meta-analysis of probiotics and GDM, Zheng et al suggested that a probiotic dose of greater than 10⁷ CFU may lead to the most benefit.³² The authors concluded that antenatal probiotic interventions had a favorable effect on glucose metabolism.³² More well-controlled trials of the efficacy of various well-characterized probiotic strains and dosages on GDM diagnosis and metabolic outcomes are needed.

Conclusions

The role of the microbiome in PEC, PTB, and GDM is not fully elucidated, although findings from this review suggest that pathogenic microbes in a variety of habitats including the placenta, oral cavity, vagina, and gut may influence the risk for adverse pregnancy outcomes. Although distinct microbial profiles were not identified in select outcomes, probiotics appear to be effective in reducing the risk for PEC, PTB, and GDM in some cases. Probiotic interventions were not associated with adverse events and were well tolerated by the participants. In studies, all three entities covered in this review, PEC, GDM, and PTB

were associated with an increase in markers of systemic inflammation.^{4,53} Future studies investigating the role of the microbiome on a variety of inflammatory pathways may help elucidate biological pathways underpinning microbial dysbiosis. Additionally, Laboratory technologies used to study the metagenomics are complex and continually evolving.⁶³ For example, the analyses can be expensive, time consuming and dependent on databases that are imperfect. Newer next-generation sequencing will likely improve accuracy.⁶³ More research in this area in conjunction with advanced molecular sequencing technologies could significantly impact perinatal outcomes for women who experience any of these high-risk complications.

Acknowledgments

Funding and Acknowledgements:

Authors Hanson and VanderVusse are currently funded on a project from the National Institute of Child Health and Human Development of the National Institutes of Health (1R21HD095320-01). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Dunlop AL, Mulle JG, Ferranti EP, Edwards S, Dunn AB, Corwin EJ. Maternal microbiome and pregnancy outcomes that impact infant health: a review. *Adv Neonatal Care*. 2015;15(6):377–385. [PubMed: 26317856]
2. Gillespie SL, Porter K, Christian LM. Adaptation of the inflammatory immune response across pregnancy and postpartum in Black and White women. *J Reprod Immunol*. 2016;114:27–31. [PubMed: 26895093]
3. Koren O, Goodrich JK, Cullender TC, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. *Cell*. 2012;150(3):470–480. [PubMed: 22863002]
4. Aagaard K, Riehle K, Ma J, et al. A metagenomic approach to characterization of the vaginal microbiome signature in pregnancy. *PLoS One*. 2012;7(6):e36466. [PubMed: 22719832]
5. Backhed F, Roswall J, Peng Y, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe*. 2015;17(6):852. [PubMed: 26308884]
6. Pelzer E, Gomez-Arango LF, Barrett HL, Nitert MD. Review: maternal health and the placental microbiome. *Placenta*. 2017;54:30–37. [PubMed: 28034467]
7. Oh KJ, Lee SE, Jung H, Kim G, Romero R, Yoon BH. Detection of ureaplasmas by the polymerase chain reaction in the amniotic fluid of patients with cervical insufficiency. *J Perinat Med*. 2010;38(3):261–268. [PubMed: 20192887]
8. Romero R, Gonzalez R, Sepulveda W, et al. Infection and labor. VIII. Microbial invasion of the amniotic cavity in patients with suspected cervical incompetence: prevalence and clinical significance. *Am J Obstet Gynecol*. 1992;167(4 Pt 1):1086–1091. [PubMed: 1415396]
9. Ramos Bde A, Kanninen TT, Sisti G, Witkin SS. Microorganisms in the female genital tract during pregnancy: tolerance versus pathogenesis. *Am J Reprod Immunol*. 2015;73(5):383–389. [PubMed: 25244611]
10. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. *Science*. 2001;292(5519):1115–1118. [PubMed: 11352068]
11. Solt I, Cohavy O. The great obstetrical syndromes and the human microbiome-a new frontier. *Rambam Maimonides Med J*. 2012;3(2):e0009. [PubMed: 23908833]
12. Amarasekara R, Jayasekara RW, Senanayake H, Dissanayake VH. Microbiome of the placenta in pre-eclampsia supports the role of bacteria in the multifactorial cause of pre-eclampsia. *J Obstet Gynaecol Res*. 2015;41(5):662–669. [PubMed: 25492799]

13. Romero R, Hassan SS, Gajer P, et al. The vaginal microbiota of pregnant women who subsequently have spontaneous preterm labor and delivery and those with a normal delivery at term. *Microbiome*. 2014;2:18. [PubMed: 24987521]
14. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature*. 2012;486(7402):207–214. [PubMed: 22699609]
15. Butler J, MacCallum I, Kleber M, et al. ALLPATHS: de novo assembly of whole-genome shotgun microreads. *Genome Res*. 2008;18(5):810–820. [PubMed: 18340039]
16. Jonasson J, Olofsson M, Monstein HJ. Classification, identification and subtyping of bacteria based on pyrosequencing and signature matching of 16s rDNA fragments. 2002. *APMIS*. 2007;115(5):668–677; discussion 678–669. [PubMed: 17504434]
17. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods*. 2010;7(5):335–336. [PubMed: 20383131]
18. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl Environ Microbiol*. 2009;75(23):7537–7541. [PubMed: 19801464]
19. VandeVusse L, Hanson L, Safdar N. Perinatal outcomes of prenatal probiotic and prebiotic administration: an integrative review. *J Perinat Neonatal Nurs*. 2013;27(4):288–301; quiz E1–2. [PubMed: 24164813]
20. Food and Agriculture Organization of the United Nations & World Health Organization (FAO/WHO). Report on Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina: FAO/WHO; 2001 <http://www.fao.org/3/a-a0512e.pdf>. Accessed August 15, 2018.
21. Roberfroid M. Probiotics: the concept revisited. *J Nutr*. 2007;137:830S–837S. [PubMed: 17311983]
22. Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics- a review. *J Food Sci Technol*. 2015;52(12):7577–7587. doi:10.1007/s13197-015-1921-1. [PubMed: 26604335]
23. Nabhani Z, Hezaveh SJG, Razmpoosh E, Asghari-Jafarabadi M, Gargari BP. The effects of synbiotic supplementation on insulin resistance/sensitivity, lipid profile and total antioxidant capacity in women with gestational diabetes mellitus: a randomized double blind placebo controlled clinical trial. *Diabetes Res Clin Pract*. 2018;138:149–157. [PubMed: 29432772]
24. Ahmadi S, Jamilian M, Tajabadi-Ebrahimi M, Jafari P, Asemi Z. The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial. *Br J Nutr*. 2016;116(8):1394–1401. [PubMed: 27681077]
25. Morris M, Boruff JT, Gore GC. Scoping reviews: establishing the role of the librarian. *JMLA*. 2016;104(4):346–354. doi:10.3163/1536-5050.104.4.020 [PubMed: 27822163]
26. Joanna Briggs Institute Levels of Evidence and Grades of Recommendation Working Party. Supporting document for the Joanna Briggs Institute Levels of Evidence and Grades of Recommendation; 2014 <https://joannabriggs.org>. Accessed August 15, 2018.
27. Lindsay KL, Walsh CA, Brennan L, McAuliffe FM. Probiotics in pregnancy and maternal outcomes: a systematic review. *J Matern Fetal Neonatal Med*. 2013;26(8):772–778. [PubMed: 23205866]
28. Barrett HL, Dekker Nitert M, Conwell LS, Callaway LK. Probiotics for preventing gestational diabetes. *Cochrane Database Syst Rev*. 2014;(2):CD009951.
29. Dallanora S, Medeiros de Souza Y, Deon RG, et al. Do probiotics effectively ameliorate glycemic control during gestational diabetes? A systematic review. *Arch Gynecol Obstet*. 2018;298:477–485.
30. Pan J, Pan Q, Chen Y, Zhang H, Zheng X. Efficacy of probiotic supplement for gestational diabetes mellitus: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med*. 2017:1–7.
31. Taylor BL, Woodfall GE, Sheedy KE, et al. Effect of probiotics on metabolic outcomes in pregnant women with gestational diabetes: a systematic review and meta-analysis of randomized controlled trials. *Nutrients*. 2017;9(5):461. doi:10.3390/nu9050461.
32. Zheng J, Feng Q, Zheng S, Xiao X. The effects of probiotics supplementation on metabolic health in pregnant women: an evidence based meta-analysis. *PLoS One*. 2018;13(5):e0197771. [PubMed: 29782556]

33. Jarde A, Lewis-Mikhael A- M, Moayyedi P, et al. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. *BMC Pregnancy Childbirth*. 2018;18(1):14. doi:10.1186/s12884-017-1629-5. [PubMed: 29310610]
34. Mendz GL, Kaakoush NO, Quinlivan JA. Bacterial aetiological agents of intra-amniotic infections and preterm birth in pregnant women. *Front Cell Infect Microbiol*. 2013;3:58. doi:10.3389/fcimb.2013.00058. [PubMed: 24137568]
35. Othman M, Alfirevic Z, Neilson JP. Probiotics for preventing preterm labour. *Cochrane Database Syst Rev*. 2007;(1):CD005941. doi:10.1002/14651858.CD005941.pub2.
36. Brantsaeter AL, Myhre R, Haugen M, et al. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. *Am J Epidemiol*. 2011;174(7):807–815. [PubMed: 21821542]
37. Ekambaram P, Jayachandran T, Venkatraman U, Leonard S. Preeclamptic cord blood hemolysis and the effect of *Monascus purpureus* and *Saccharomyces cerevisiae* in modulating preeclamptic stress. *Bratisl Lek Listy*. 2013;114(9):508–513. [PubMed: 24020706]
38. Nordqvist M, Jacobsson B, Brantsaeter AL, Myhre R, Nilsson S, Sengpiel V. Timing of probiotic milk consumption during pregnancy and effects on the incidence of preeclampsia and preterm delivery: a prospective observational cohort study in Norway. *BMJ Open*. 2018;8(1):e018021.
39. Dolatkhan N, Hajifaraji M, Abbasalizadeh F, Aghamohammadzadeh N, Mehrabi Y, Abbasi MM. Is there a value for probiotic supplements in gestational diabetes mellitus? a randomized clinical trial. *J Health Popul Nutr*. 2015;33:25. doi:10.1186/s41043-015-0034-9. [PubMed: 26825666]
40. Hajifaraji M, Jahanjou F, Abbasalizadeh F, Aghamohammadzadeh N, Mesgari M, Dolatkhan N. Effect of probiotic supplements in women with gestational diabetes mellitus on inflammation and oxidative stress biomarkers: a randomized clinical trial. *Asia Pac J Clin Nutr*. 2018;27(3):581–591. [PubMed: 29737805]
41. Jafarnejad S, Saremi S, Jafarnejad F, Arab A. Effects of a multispecies probiotic mixture on glycemic control and inflammatory status in women with gestational diabetes: a randomized controlled clinical trial. *J Nutr Metab*. 2016;2016:5190846. [PubMed: 27429803]
42. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. *Diabetes Metab*. 2016;42(4):234–241. doi:10.1016/j.diabet.2016.04.009. [PubMed: 27209439]
43. Kijmanawat A, Panburana P, Reutrakul S, Tangshewinsirikul C. Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: a double-blind randomized controlled trial. *J Diabetes Investig*. 2018;520. doi:10.1111/jdi.12863.
44. Lindsay KL, Brennan L, Kennelly MA, et al. Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. *Am J Obstet Gynecol*. 2015;212(4):496.e1–11. [PubMed: 25687568]
45. Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. *Br J Nutr*. 2010;104(S1):1792–1799.
46. Wickens KL, Barthow CA, Murphy R, et al. Early pregnancy probiotic supplementation with *Lactobacillus rhamnosus* HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. *Br J Nutr*. 2017;117(6):804–813. [PubMed: 28367765]
47. Kirihara N, Kamitomo M, Tabira T, Hashimoto T, Taniguchi H, Maeda T. Effect of probiotics on perinatal outcome in patients at high risk of preterm birth. *J Obstet Gynaecol Res*. 2018;44(2):241–247. [PubMed: 28994162]
48. Krauss-Silva L, Moreira ME, Alves MB, et al. A randomised controlled trial of probiotics for the prevention of spontaneous preterm delivery associated with bacterial vaginosis: preliminary results. *Trials*. 2011;12:239. doi:10.1186/1745-6215-12-239. [PubMed: 22059409]
49. Myhre R, Brantsaeter AL, Myking S, et al. Intake of probiotic food and risk of spontaneous preterm delivery. *Am J Clin Nutr*. 2011;93:151–157. [PubMed: 20980489]
50. DiGiulio DB, Gervasi M, Romero R, et al. Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. *J Perinat Med*. 2010;38(5):503–513. [PubMed: 20482470]

51. Jaramillo A, Arce R, Contreras A, Herrera JA. Effect of periodontal therapy on the subgingival microbiota in preeclamptic patients. *Biomedica*. 2012;32(2):233–238. [PubMed: 23242297]
52. Nizyaeva N, Lyubasovskaya L, Gordeev A, Dubodelov D, Pripitnevich T, Shchegolev A. The disturbance of opportunistic placenta microflora as a trigger for preeclampsia pathogenesis. *Virchows Arch*. 2017;471(1):S97.
53. Liu J, Yang H, Yin Z, et al. Remodeling of the gut microbiota and structural shifts in preeclampsia patients in South China. *Eur J Clin Microbiol Infect Dis*. 2017;36(4):713–719. [PubMed: 27988814]
54. Crusell MKW, Hansen TH, Nielsen T, et al. Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum. *Microbiome*. 2018;6(1):89. [PubMed: 29764499]
55. Kuang YS, Lu JH, Li SH, et al. Connections between the human gut microbiome and gestational diabetes mellitus. *Gigascience*. 2017;6(8):1–12.
56. Wang J, Zheng J, Shi W, et al. Dysbiosis of maternal and neonatal microbiota associated with gestational diabetes mellitus. *Gut*. 2018.
57. Zheng NN, Guo XC, Lv W, Chen XX, Feng GF. Characterization of the vaginal fungal flora in pregnant diabetic women by 18S rRNA sequencing. *Eur J Clin Microbiol Infect Dis*. 2013;32(8):1031–1040. [PubMed: 23463448]
58. Ardisson AN, de la Cruz DM, Davis-Richardson AG, et al. Meconium microbiome analysis identifies bacteria correlated with premature birth. *PLoS One*. 2014;9(3):e90784. [PubMed: 24614698]
59. Avershina E, Slangsvold S, Simpson MR, et al. Diversity of vaginal microbiota increases by the time of labor onset. *Sci Rep*. 2017;7(1):17558. [PubMed: 29242550]
60. Brown RG, Marchesi JR, Lee YS, et al. Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. *BMC Med*. 2018;16(1):9. [PubMed: 29361936]
61. Dahl C, Stanislawski M, Iszatt N, et al. Gut microbiome of mothers delivering prematurely shows reduced diversity and lower relative abundance of Bifidobacterium and Streptococcus. *PLoS One*. 2017;12(10):e0184336. [PubMed: 29069100]
62. Doyle RM, Alber DG, Jones HE, et al. Term and preterm labour are associated with distinct microbial community structures in placental membranes which are independent of mode of delivery. *Placenta*. 2014;35(12):1099–1101. [PubMed: 25458966]
63. Hyman RW, Fukushima M, Jiang H, et al. Diversity of the vaginal microbiome correlates with preterm birth. *Reprod Sci*. 2014;21(1):32–40. [PubMed: 23715799]
64. Subramaniam A, Kumar R, Cliver SP, et al. Vaginal microbiota in pregnancy: evaluation based on vaginal flora, birth outcome, and race. *Am J Perinatol*. 2016;33(4):401–408. [PubMed: 26479170]
65. Tabatabaei N, Eren AM, Barreiro LB, et al. Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study. *BJOG*. 2018.
66. Wylie KM, Wylie TN, Cahill AG, Macones GA, Tuuli MG, Stout MJ. The vaginal eukaryotic DNA virome and preterm birth. *Am J Obstet Gynecol*. 2018;219(2):189.e1–e12. [PubMed: 29738749]
67. Chaiworapongsa T, Chaemsaitong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. *Nat Rev Nephrol*. 2014;10(8):466–480. [PubMed: 25003615]
68. Minassian C, Thomas SL, Williams DJ, Campbell O, Smeeth L. Acute maternal infection and risk of pre-eclampsia: a population-based case-control study. *PLoS One*. 2013;8(9).
69. Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. *Am J Obstet Gynecol*. 2008;198(1):7–22. [PubMed: 18166297]
70. Shukla SK, Meier PR, Mitchell PD, Frank DN, Reed KD. *Leptotrichia amnionii* sp. nov., a novel bacterium isolated from the amniotic fluid of a woman after intrauterine fetal demise. *J Clin Microbiol*. 2002;40(9):3346–3349. [PubMed: 12202577]
71. Mitchell CM, Hitti JE, Agnew KJ, Fredricks DN. Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria. *BMC Infect Dis*. 2009;9:89. [PubMed: 19515236]

72. Cobb CM, Kelly PJ, Williams KB, Babbar S, Angolkar M, Derman RJ. The oral microbiome and adverse pregnancy outcomes. *Int J Womens Health*. 2017;9:551–559. [PubMed: 28848365]
73. Zahumensky J, Hederlingova J, Psenkova P. [The importance of maternal microbiome in pregnancy]. *Ceska Gynekol*. 2017;82(3):211–217. [PubMed: 28593775]
74. Madianos PN, Bobetsis YA, Offenbacher S. Adverse pregnancy outcomes (APOs) and periodontal disease: pathogenic mechanisms. *J Periodontol*. 2013;84(4 Suppl):S170–180. [PubMed: 23631577]
75. Olsen I From the Acta Prize Lecture 2014: the periodontal-systemic connection seen from a microbiological standpoint. *Acta Odontol Scand*. 2015;73(8):563–568. [PubMed: 25891035]
76. Wei BJ, Chen YJ, Yu L, Wu B. Periodontal disease and risk of preeclampsia: a meta-analysis of observational studies. *PLoS One*. 2013;8(8):e70901. [PubMed: 23951033]
77. Lima VJ, Andrade CR, Ruschi GE, Sass N. Serum lipid levels in pregnancies complicated by preeclampsia. *Sao Paulo Med J*. 2011;129(2):73–76. [PubMed: 21603783]
78. James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. *J Pathol*. 2010;221(4):363–378. [PubMed: 20593492]
79. van Baarlen P, Troost F, van der Meer C, et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. *Proc Natl Acad Sci USA*. 2011;108 Suppl 1:4562–4569. [PubMed: 20823239]
80. Guerby P, Vidal F, Garoby-Salom S, et al. [Oxidative stress and preeclampsia: A review]. *Gynecol Obstet Fertil*. 2015;43(11):751–756. [PubMed: 26476891]
81. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med*. 1998;15(7):539–553. [PubMed: 9686693]
82. Landon MB, Gabbe SG. Gestational diabetes mellitus. *Obstet Gynecol*. 2011;118(6):1379–1393. doi:10.1097/AOG.0b013e31823974e2. [PubMed: 22105269]
83. Allalou A, Nalla A, Prentice KJ, et al. A predictive metabolic signature for the transition from Gestational Diabetes Mellitus to Type 2 Diabetes. *Diabetes*. 2016;65(9):2529–2539. doi:10.2337/db15-1720. [PubMed: 27338739]
84. DiGiulio DB, Callahan BJ, McMurdie PJ, et al. Temporal and spatial variation of the human microbiota during pregnancy. *Proc Natl Acad Sci USA*. 2015;112(35):11060–11065. [PubMed: 26283357]
85. Ravel J, Gajer P, Abdo Z, et al. (2011). Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci USA*. 108(Suppl. 1):4680–4687. doi:10.1073/pnas.1002611107. [PubMed: 20534435]
86. Reid G, Bocking A. The potential for probiotics to prevent bacterial vaginosis and preterm labor. *Am J Obstet Gynecol*. 2003;189(4):1202–1208. [PubMed: 14586379]
87. Salas-Jara MJ, Ilabaca A, Vega M, García A. Biofilm forming *Lactobacillus*: new challenges for the development of probiotics. Kitazawa H, Villena J, eds. *Microorganisms*. 2016;4(3):35. doi: 10.3390/microorganisms4030035.
88. Reid G, Dols J, Miller W. Targeting the vaginal microbiota with probiotics as a means to counteract infections. *Curr Opin Clin Nutr Metab Care*. 2009;12:583–587. [PubMed: 19741517]
89. Goldenberg 2000 Goldenberg RL, Hauth JC, Andrews WW. Intrauterine Infection and Preterm Delivery. *N Engl J Med*. 2000;342:1500–1507. <https://www.nejm.org/doi/full/10.1056/nejm200005183422007>. Accessed August 15, 2018. doi:10.1056/NEJM200005183422007. [PubMed: 10816189]
90. Yang S, Reid G, Challis JRG, Kim SO, Gloor GB, Bocking AD. Is there a role for probiotics in the prevention of preterm birth? *Front Immunol*. 2015;6:62. doi:10.3389/fimmu.2015.00062. [PubMed: 25741339]
91. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. *Am J Med*. 1983;74:14–22. [PubMed: 6600371]
92. Gomez-Arango LF, Barrett HL, McIntyre HD, Callaway LK, Morrison M, Dekker Nitert M. Increased systolic and diastolic blood pressure is associated with altered gut microbiota composition and butyrate production in early pregnancy. *Hypertension*. 2016;68(4):974–981. [PubMed: 27528065]

93. Hanson L, VandeVusse L, Abad S, Safdar N. Probiotics for treatment and prevention of urogenital infections in women: a systematic review. *J Midwifery Womens Health*. 2016;61:339–355. [PubMed: 27218592]
94. Stone LP, Stone PM, Rydbom EA, et al. Customized nutritional enhancement for pregnant women appears to lower incidence of certain common maternal and neonatal complications: an observational study. *Glob Adv Health Med*. 2014;3(6):50–55. doi:10.7453/gahmj.2014.053. [PubMed: 25568832]
95. Mor G, Kwon JY. Trophoblast-microbiome interaction: a new paradigm on immune regulation. *Am J Obstet Gynecol*. 2015;213(4Suppl):S131–S137. [PubMed: 26428492]

Figure 1.
PRISMA 2009 Flow Diagram

Table 1.

PubMed.gov Search Strategies. Date searched: August 10, 2018, Chrome browser.

Preeclampsia	((("microbiota"[MeSH Terms] OR "microbiota"[tiab] OR "microbiome"[tiab] OR pre-biotic[tiab] OR pre-biotics[tiab] OR "prebiotics"[MeSH Terms] OR "prebiotics"[tiab] OR "prebiotic"[tiab] OR "probiotics"[MeSH Terms] OR "probiotics"[tiab] OR "probiotic"[tiab]) AND (preeclampsia[tiab] OR pre-eclampsia[tiab] OR "Pre-Eclampsia"[Mesh])) AND ("2008/08/10"[PDAT] : "2018/08/10"[PDAT]) AND english[All Fields])
Preterm Birth	((("microbiota"[MeSH Terms] OR "microbiota"[tiab] OR "microbiome"[tiab] OR pre-biotic[tiab] OR pre-biotics[tiab] OR "prebiotics"[MeSH Terms] OR "prebiotics"[tiab] OR "prebiotic"[tiab] OR "probiotics"[MeSH Terms] OR "probiotics"[tiab] OR "probiotic"[tiab]) AND ("Premature Birth"[Mesh Terms] OR "premature birth"[tiab] OR "preterm birth"[tiab] OR "pre-term birth"[tiab])) AND ("2008/08/10"[PDAT] : "2018/08/10"[PDAT]) AND english[All Fields])
Gestational Diabetes Mellitus	((("microbiota"[MeSH Terms] OR "microbiota"[tiab] OR "microbiome"[tiab] OR pre-biotic[tiab] OR pre-biotics[tiab] OR "prebiotics"[MeSH Terms] OR "prebiotics"[tiab] OR "prebiotic"[tiab] OR "probiotics"[MeSH Terms] OR "probiotics"[tiab] OR "probiotic"[tiab]) AND ("Diabetes, Gestational"[Mesh] OR "gestational diabetes"[tiab])) AND ("2008/08/10"[PDAT] : "2018/08/10"[PDAT]) AND english[All Fields])

Table 2.

Systematic review and meta-analyses

Author/Year	Systematic Review	Meta-analysis	Articles included	Intervention if applicable	Findings related to intervention if applicable	
					Significant	Nonsignificant or (NA) statistics not provided
Preeclampsia (PEC)						
Lindsay ²⁷ , 2013 [#]	x		7	Probiotics	↓ preeclampsia (OR=0.80, 95% CI: 0.66–0.96) and severe preeclampsia (OR=0.61, 95% CI: 0.43–0.89)	NA: ↓ preeclampsia
Gestational Diabetes Mellitus (GDM)						
Barrett, ²⁸ 2014	x		1	Probiotics	↓ diagnosis of GDM (<i>P</i> =0.03)	
Dallanora, ²⁹ 2018	x		7	Probiotics		NA: Probiotics may improve glycemic control, ↓VLDL Cholesterol, ↓ inflammatory marker,
Lindsay, ²⁷ 2013	x		7	Probiotics		NA: ↓ fasting blood sugar, incidence of GDM
Pan, ³⁰ 2017	x	x	6	Probiotics	↓ fasting serum insulin (<i>P</i> =0.00001), HOMA (<i>P</i> =0.02)	FBS (<i>P</i> =0.9), gestational age (<i>P</i> =0.63), birth weight (<i>P</i> =0.9)
Taylor, ³¹ 2017	x	x	4	Probiotic	↓ HOMA (<i>P</i> =0.01)	FBS (<i>P</i> =0.96), LDL-cholesterol (<i>P</i> =0.67), weight gain, mode of birth, neonatal outcomes, adverse events (P levels not reported)
Zheng, ³² 2018		x	10	Probiotics	↓ fasting serum insulin (<i>P</i> =0.0001), HOMA (<i>P</i> =0.03)	FBS (<i>P</i> =0.26), Lipid levels (<i>P</i> =0.71), HDL Cholesterol (<i>P</i> =0.87), LDL Cholesterol (<i>P</i> =0.97), Triglycerides (0.29)
Spontaneous premature labor (sPTL) and/or premature birth (sPTB)						
Jarde, ³³ 2018	x	x	49	Probiotic Prebiotic		PTL <34 weeks (<i>P</i> =0.96), or <37 weeks (<i>P</i> =0.96); PTL <37 weeks (<i>P</i> =0.73), or <37 weeks (<i>P</i> =0.83)
Mendz, ³⁴ 2013	x		13	N/A		NA: Vaginal bacteria were the most common source of intra-amniotic infection.
Othman, ³⁵ 2007	x	x	3	Probiotics	↓ genital infection with probiotics (<i>P</i> =0.00096)	PTB <32 weeks (<i>P</i> =0.79), PTB <37 weeks (<i>P</i> =0.26)

Note:

[#] same systematic review noted below.

Abbreviations: BV=Bacterial Vaginosis; hs-CRP=C-Reactive Protein; FBS=Fasting Blood Sugar; HOMA=Homeostatic Model Assessment for Insulin Resistance; IFN=Interferon; IL=Interleukin; TAC=Total Antioxidant Capacity; TNF- α =Tumor Necrosis Factor; VDL=Very Low Density; TAG=Total Available Glucose.

Table 3:

Summary of Probiotics Studies

Author/Year	Study Design	Total Participants	Sample and microbial intervention [#]	Purpose	Findings related to intervention	
					Significant	Nonsignificant
Preeclampsia (PEC)						
Branstater, ³⁶ 2011	Prospective Cohort	33,399 women	Probiotic milk	Risk of PEC	↓PEC risk $P<0.05$, ↓Severe PEC risk with daily consumption ($P<0.05$), ↓Severe PEC risk, with weekly and daily probiotic milk intake ($P<0.05$)	
Ekambaram, ³⁷ 2015	Case-Control	20-Cases 20-Controls	Probiotic yeasts (M. purpureus, S. cerevisiae)	Antihemolytic and antioxidant efficiency of probiotic yeasts on fetal red blood cells in infants of women with PEC	M. purpureus showed significant reactive oxygen radical scavenging activity (p<0.001), S. cerevisiae: significant nitric oxide radical scavenging activity (p<0.001), oxidative stress hemolysis decreased in both groups	Dose response
Nordqvist, ³⁸ 2018 [#]	Prospective Cohort	Norwegian women	Probiotic milk	Intervention timing and incidence of PEC	Probiotic milk intake during late pregnancy intake ↓PE ($P=0.007$)	
Gestational Diabetes Mellitus (GDM)						
Ahmadi, ²⁴ 2016	RCT	70-GDM	35-Synbiotic 35-Placebo	Insulin metabolism Lipid profiles	↓serum insulin ($P<0.005$), HOMA insulin resistance ($P=0.003$), HOMA β cell	

Author/Year	Study Design	Total Participants	Sample and microbial intervention [#]	Purpose	Findings related to intervention	
					Significant	Nonsignificant
					function ($P=0.008$), insulin sensitivity check index ($P=0.02$), serum TAG ($P<0.001$)	
Dolatkhah, ³⁹ 2015	RCT	64-GDM	32-Probiotic 32-Placebo	Glucose metabolism Weight gain	↓pregnancy weight gain study weeks 5 and 6, ($P<0.05$), FBS ($P<0.05$), insulin resistance index ($P<0.05$)	Pregnancy weight gain (study weeks 1–4)
Hajifaraji, ⁴⁰ 2018	RCT	GDM	Probiotic	Inflammation Oxidative stress		
Jafarnejad, ⁴¹ 2016	RCT	82-GDM	41-Probiotic 41-Placebo	Glycemic control Inflammatory status	↓IL-6 ($P=0.04$), TNF- α ($P=0.04$), hs-CRP ($P=0.03$)	FBS, HbA1c, HOMA, IL-10, insulin levels
Karamali, ⁴² 2016	RCT	60-GDM	30-Probiotic 30-Placebo	Glycemic control Lipid profiles	↓FBS ($P<0.001$), serum insulin levels ($P<0.001$), HOMA ($P=0.03$), insulin sensitivity ($P<0.0007$), triglycerides ($P=0.03$), VDL cholesterol ($P=0.03$)	Lipid profiles
Kijmanawat, ⁴³ 2018	RCT	60-GDM	28-Probiotic 29-Placebo	Insulin Resistance	↓FBS ($P=0.34$), fasting plasma insulin ($P=0.001$), HOMA ($P=0.001$)	Pregnancy weight gain
Lindsay, ⁴⁴ 2015	RCT	149-GDM	74-Probiotic 75 Placebo	Metabolic health	↓Total Cholesterol ($P=0.031$), LDL Cholesterol ($P=0.011$)	FBS ($P=0.588$), Insulin ($P=0.927$), HOMA ($P=0.875$), C-Peptide ($P=0.843$), HDL Cholesterol ($P=0.341$), Triglycerides

Author/Year	Study Design	Total Participants	Sample and microbial intervention [#]	Purpose	Findings related to intervention	
					Significant	Nonsignificant
Luoto, ⁴⁵ 2010	RCT	256 gravidas	67-Probiotic and dietary intervention 63-Placebo and dietary intervention 85-Control and Placebo	Pregnancy outcome and prenatal and postnatal growth	Probiotic plus dietary intervention ↓GDM ($P=0.003$)	($P=0.687$), HDL ratio ($P=0.704$), LDL ratio ($P=0.244$)
Nabhani, ²³ 2018	RCT	90-GDM	48-Synbiotic 49-Placebo	Insulin resistance Lipid profile Total antioxidant capacity	The synbiotic intervention resulted in decreased LDLs from baseline ($P<0.05$), ↓SBP and DBP in synbiotic group compared to placebo ($P<0.05$).	FBS, Insulin resistance/sensitivity, lipid profile, TAC indices
Wickens, ⁴⁶ 2017	RCT	Healthy pregnant women	212-Probiotic 211-Placebo	GDM prevalence	↓GDM in women 35 years old ($P=0.009$) and women with history of GDM ($P=0.004$)	Overall GDM prevalence ($P=0.08$)
Spontaneous Premature Labor (sPTL) and/or Spontaneous Premature Birth (sPTB)						
Kirihaara, ⁴⁷ 2018	Retrospective Cohort	121	45-Probiotic 76-Controls	Perinatal outcomes sPTB	↑Gestation age ($P=0.012$), ↓sPTB <32 weeks ($P=0.001$), ↓CAM ($P=0.03$), ↓vaginal <i>Lactobacillus</i> ($P=0.052$)	Funinitis ($P=0.052$), birth weight ($P=0.021$)
Krauss-Silva, ⁴⁸ 2011	RCT	644 asymptomatic gravidas	320-Probiotic 324-Placebo	Prevention of PTB associated BV		Preliminary results: sPTD <34 weeks ($P=0.31$), sPTD <37 weeks ($P=0.14$)
Myhre, ⁴⁹ 2011	Prospective cohort study	23,822 healthy gravidas	950-Probiotic milk 17,938-Controls	sPTB risk	↓sPTB with high intake or	

Author/Year	Study Design	Total Participants	Sample and microbial intervention [#]	Purpose	Findings related to intervention	
					Significant	Nonsignificant
Nordqvist, ³⁸ 2018	Prospective Cohort	37,050 Norwegian women	Probiotic milk	Intervention timing and incidence of PTL	probiotic milk ($P<0.035$)	Dose response
					Probiotic milk intake during early pregnancy intake ,PTL ($P=0.03$)	

Note:

[#] For details about metagenomic classifications-see the original publication

Abbreviations: BV=Bacterial Vaginosis; hs-CRP=C-Reactive Protein; FBS=Fasting Blood Sugar; HOMA= Homeostatic Model Assessment for Insulin Resistance; IFN=Interferon; IL=Interleukin; TAC= Total Antioxidant Capacity; TNF- α =Tumor Necrosis Factor; VDL=Very Low Density; TAG= Total Available Glucose.

Table 4:

Summary Table of Microbiome Studies, often Metagenomic-Based

Author Year	Study Design	Total Participants	Microbiome Site Studied	Findings
Preeclampsia				
DiGiulio, ⁵⁰ 2010	Retrospective Cohort	62	Intra-amniotic	Women with PEC with MIAC demonstrated a ↑ mean amniotic fluid IL-6 level ($p=0.002$).
Jaramillo, ⁵¹ 2012	Secondary analysis of RCT	57	Oral	RCT was on: subgingival scaling and planing vs supragingival prophylaxis. No differences in periodontopathic organisms between the two groups.
Amarasekara, ¹² 2015	Nested Case-Control	110: 55 cases, 55 controls	Placenta	12.7% of the placenta samples of women with PEC were PCR positive for the 16S rRNA gene. Pathogenic microbiome identified: <i>Listeria</i> , <i>Salmonella</i> , and <i>Escherichia</i> .
Nizyaeva, ⁵² 2017	Case-Control	32: 20 cases, 12 controls	Placenta	25% of the PEC group demonstrated pathologic microbial growth control group placentas were culture negative. Placental microbes were only identified in women with PEC who delivered after 34 weeks of gestation
Liu, ⁵³ 2017	Case-Control	100: 26 1 st trimester 24 2 nd trimester 24 3 rd trimester 26 controls)	Gut	Women with PEC; there was an overall ↑ in pathogenic bacteria. <i>Clostridium perfringens</i> ($= .03$) and <i>Bulleidia moorei</i> ($P=0.00$) ↑ in women with PEC decrease noted in the probiotic bacteria <i>Coprococcus catus</i> ($P=0.03$).
Gestational Diabetes				
Crusell, ⁵⁴ 2018	Prospective cohort	50 GDM, 157 controls	Gut	GDM associated with significant gut microflora disruption similar to that found in nonpregnant adults with Type 2 diabetes*
Kuang, ⁵⁵ 2017	Exploratory descriptive	124: 43 GDM, 81 healthy	Stool in 2 nd trimester	Significant differences in microbiomes of women with or without GDM. ↓ diversity noted with GDM women.
Wang, ⁵⁶ 2018	Descriptive	346 women with GDM & 140 of their NBs, to total of 581 women, 248 NBs = 1,062 samples	Oral, pharynx, GI, vagina, meconium, amniotic fluid	<i>Lactobacillus iners</i> strains were significantly > in those with GDM ($P<.05$). Also ↑ viral load in meconium of NBs whose mothers have GDM. Microbial variations showed convergence across body sites with more similar community structure in those with GDM.
Zheng, ⁵⁷ 2013	Descriptive comparison	105, in 4 groups: HP=31, GDM=39, T1DM=35, HN=32	Vagina, for fungal flora	Fasting Plasma Glucose (FPG), 1- and 2-hour plasma glucose levels, & HbA _{1c} were always ↑ in GDM and Type 1 DM groups ($P<0.01$). Diversity in fungi > by pregnancy group, ↑ from 13, 17, and 20 species respectively in HP, GDM, and T1DM groups
Preterm Birth				
Ardisson, ⁵⁸ 2014	Descriptive	52 infants: (23–41 weeks at birth)	Meconium	Gestational age prior to 33 weeks at birth had largest influence on microbial community structure ($P=0.029$); mode of delivery (C/Sec versus vaginal) also had effect ($P=0.044$). Associated bacteria seen in PTBs: <i>Enterobacter</i> , <i>Enterococcus</i> , <i>Lactobacillus</i> , <i>Photobacterium</i> , & <i>Tannerella</i> .
Avershina, ⁵⁹ 2017	From RCT (about allergy prevention)	335: 256 @36 wks, 105 in labor	Vagina	Swabs at 36 weeks or labor admission: at labor onset had ↑ α-diversity and ↑ closer to labor.

Author Year	Study Design	Total Participants	Microbiome Site Studied	Findings
Brown, ⁶⁰ 2018	Prospective cohort	250 women with history of early loss	Vagina	In those with PTBs (38/250=15%) compared to term births, <i>Lactobacillus</i> was depleted prior to PPRM ($P=0.026$), which occurred at mean gestational age of 30 weeks, and depletion persisted after PPRM ($P=0.005$). Dysbiosis also occurred in women with high amounts of <i>Lactobacillus</i> when treated with Erythromycin ($P=0.00009$), as did NB sepsis.
Dahl, ⁶¹ 2017	Prospective cohort, case control	121 births: 102 term, 19 = PTB	Stool at 4 days post-partum	If PTBs, had lower α -diversity in gut and significantly fewer OTUs in genera of <i>Bifidobacterium</i> & <i>Streptococcus</i> & families in Clostridiales order, (stats not available)
Doyle, ⁶² 2014	Cross-sectional study	989,258 (26.1%) with chorio, 120 (12.1%) had severe	Placenta	Non-severe chorioamnionitis (defined as ≥ 25 neutrophils granulocytes on average per 10 high power field) showed difference in community members, $\uparrow$ bacterial load, higher phylogenetic diversity, $\downarrow$ species richness, and smaller (shorter) newborns
Hyman, ⁶³ 2014	Prospective cohort	88: 17 PTBs, 71 term births	Vagina	Significant correlation between race/ethnicity and diversity (used Shannon Diversity Index) Location of sampling matters (prefer posterior fornix). Small sample size with limited statistical analysis
Subramaniam, ⁶⁴ 2016	Retrospective, stratified by race, BV, & PTB	40 prior taken vaginal swabs at 21–25 weeks, & Nugent smears	Vagina	BV samples had $>$ diversity ($P < .05$), with more abundant BV associated bacteria. Underpowered to compare PTB with microbiome, but may be that changes in communities are linked to sPTBs rather than specific organisms.
Tabatabaei, ⁶⁵ 2018	Nested case-control in cohort	450: 17 early sPTBs, 77 late sPTBs, & 356 controls	Vagina	$\uparrow$ diversity ($P < 0.05$) in CST IV. Presence of BV-associated bacteria (<i>Gardnerella vaginalis</i> , <i>Atopobium vaginae</i> , and <i>Veillonellaceae</i> bacterium) also associated with PTB
Wylie, ⁶⁶ 2018	Nested case-control in prospective cohort study	60: 128 swabs through PG	Vagina, for virome	24 had PTBs (38.7%). African American women were 65% of sample. Higher viral richness was associated w/ PTB in total sample ($P=0.0005$) and African American subgroup ($P=0.0003$). Both high diversity of bacteria & viruses in 1 st trimester was associated with $\uparrow$ risk for sPTB ($P=0.01$); $\downarrow$ combined diversity with term birth ($P < 0.0001$).

Note: Abbreviations: GDM=Gestational Diabetes Mellitus; HN=healthy non-pregnant; HP=healthy pregnant; MIA=microbial invasion of the amniotic cavity; NB=newborn; OTUs=operational taxonomic units are clustered, grouped sequences; PE=preeclampsia; PG=pregnancy; PTL=Preterm Labor; PTB=Preterm Birth; sPTB=spontaneous preterm birth; T1DM=Type 1 Diabetes Mellitus